Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 951–1000 of 18397
The Board of Directors of the Company has appointed Mr. Cimino as the Company’s Interim Chief Financial Officer to serve as the Company’s principal financial officer and principal accounting officer effective June 5, 2025.
On June 11, 2025, David Natan resigned from his role as Chief Financial Officer of The Crypto Company (the “Company”)
Effective upon Mr. Natan’s resignation, on June 11, 2025, the board of directors of the Company appointed Ronald Levy to serve as the Company’s interim Chief Financial Officer.
Randy Milby pursuant to which he resigned for personal reasons from his positions as Chief Executive Officer and member of the Board of Directors, effective immediately.
the Board appointed Sireesh Appajosyula as the Company’s Chief Executive Officer, effective immediately.
On June 11, 2025, the board of directors (the “Board”) of the Company appointed Anthony Baldor, to serve as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 15, 2025.
On June 10, 2025, Brigid Makes notified Vivani Medical, Inc. (the “Company”) of her decision to resign from her role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, of the Company, effective as of June 15, 2025.
On June 10, 2025, Timothy Fitzsimmons, Chief Financial Officer (“CFO”) of CompoSecure, Inc. (the “Company”) informed the Company’s Board of Directors that he will retire from his position
Also on June 5, 2025, the Board appointed Donna Guy to serve as the Company’s Chief Financial Officer.
On June 6, 2025, the ABM Industries Incorporated (the “Company”) Board of Directors (the “Board”) appointed David Orr to serve as the Company’s Executive Vice President and Chief Financial Officer, effective immediately.
On June 6, 2025, Earl Ellis terminated from the position of chief financial officer.
On June 4, 2025, Kerri-Ann Millar notified the Company that she is resigning from her position as Chief Financial Officer, effective June 13, 2025.
Effective June 13, 2025, Daniel R. Passeri, the Company’s Chief Executive Officer, will serve as the Company’s principal financial and accounting officer on an interim basis until a new principal financial and accounting officer is designated.
D. Christopher Monroe, the Company’s Chief Financial Officer, will separate from the Company, effective as of June 9, 2025.
Departure of Chief Financial Officer Patrick Reilly, Chief Financial Officer and Principal Accounting Officer of Angel Studios, Inc, (the “Company”), voluntarily resigned from his position, effective as of June 4, 2025.
Appointment of New Chief Financial Officer On June 4, 2025, the Company announced the appointment of Scott Klossner as the Company’s Chief Financial Officer and Principal Accounting Officer.
On June 4, 2025, the Company executed an offer letter with Naveen Chopra for the position of Chief Financial Officer, with an expected start date of June 30, 2025.
Michael Guthrie will cease serving in the capacity of Chief Financial Officer and Principal Financial Officer of the Company upon the effective date of Mr. Chopra’s appointment
The Company has appointed Ms. Vasquez, age 50, to succeed Mr. Thanisch as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, effective June 23, 2025.
Scott Thanisch will no longer serve as the Executive Vice President, Chief Financial Officer and Treasurer of Orion Group Holdings, Inc. (the “Company”) effective June 23, 2025.
Effective June 9, 2025, Jake Singleton separated from our company as our Chief Financial Officer.
Effective June 10, 2025, our Board of Directors (the “Board”) appointed Scott J. Bowman as our Chief Financial Officer.
On June 10, 2025, Corpay, Inc. (the "Company" or "Corpay") announced the appointment of Peter Walker as Chief Financial Officer ("CFO"), effective July 21, 2025.
interim CFO Alissa Vickery will return to her full-time role as Chief Accounting Officer.
the Board of Directors appointed Michael Howe, currently a member of the Board of Directors, to serve as Chief Executive Officer of the Company, effective June 10, 2025.
On June 10, 2025, Kraig Higginson, Chief Executive Officer of Aspire Biopharma Holdings, Inc. (the “Company”), notified the Board of Directors of his intention to step down from the role of Chief Executive Officer, effective June 10, 2025.
the board of directors of the Company has appointed Mr. Guojian Chen as Chief Executive Officer of the Company, effective June 10, 2025.
Mr. Shaoke Li recently tendered to the board of directors his resignation from the positions of Chief Executive Officer and Director of DT Cloud Acquisition Corporation (the “Company”), effective June 10, 2025.
terminated the employment of David Beers, its Chief Financial Officer without cause
appointed Joseph DosSantos, its current Senior Vice President Finance, as the Company's interim CFO while the Company conducts a search for a new CFO.
As of the Effective Date, Mr. Uhlick will also serve as Star Holdings’ (the “Company”) Chief Accounting Officer and succeed Brett Asnas as principal accounting officer.
Andrew C. Warren, the Company’s Strategic Advisor to the Office of the CEO, will assume the additional duties of Executive Vice President, Interim Chief Financial Officer and principal financial officer of the Company after the departure of Mr. Chopra.
On June 3, 2025, Naveen Chopra, the Executive Vice President, Chief Financial Officer of Paramount Global (the “Company”), notified the Company of his decision to resign from his position, effective June 27, 2025.
Mr. Snyder is succeeding Mr. Thomas Amato, the current President and Chief Executive Officer of the Company.
appointed Mr. Thomas Snyder to the position of President and Chief Executive Officer of the Company (" CEO "), effective as of June 23, 2025
Daniel Cunha will become Chief Financial Officer of the Company, effective July 1, 2025.
On June 5, 2025, the Board of Directors appointed Jeanette M. Bjorkquist to serve as the Company’s principal financial officer in addition to her role as principal accounting officer.
Ms. Bjorkquist succeeds Jason A. Okazaki, who previously served as both the Company’s principal executive officer and principal financial officer.
Effective as of the Separation Date, the Board appointed Tammy Furlong, age 54, the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, to succeed Mr. Ferra as President and Interim Chief Executive Officer
In connection with the Merger, the Company terminated the employment of Joseph J. Ferra, Jr., as the Company’s President, Chief Executive Officer, effective as of June 30, 2025
On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.
Navid Mahmoodzadegan, Co-Founder and Co-President, will succeed Mr. Moelis as Chief Executive Officer and will also join the Board of Directors of the Company.
Scott Behrens will cease to serve as Executive Vice President, Chief Financial Officer and Chief Accounting Officer of the Company effective July 1, 2025.
On June 9, 2025, ACI Worldwide, Inc. (the “Company”) announced the appointment of Robert Leibrock as its Chief Financial Officer and Chief Accounting Officer effective July 1, 2025.
On June 9, 2025, Symbotic Inc. (the “Company”) announced the appointment of Izilda “Izzy” Martins as Chief Financial Officer and principal financial officer of the Company, effective August 9, 2025.
the following officers resigned from the offices indicated besides such officers’ names and ceased to serve in such offices: Kendall K. Young Chief Executive Officer and President Nicholas R. Balzo Chief Financial Officer and Treasurer Ann B. Harrington General Counsel and Secretary
the following officers resigned from the offices indicated besides such officers’ names and ceased to serve in such offices: Kendall K. Young Chief Executive Officer and President Nicholas R. Balzo Chief Financial Officer and Treasurer Ann B. Harrington General Counsel and Secretary
On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”).
On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.
Mr. Michael W. Sumruld will join the Company as Senior Vice President of Finance on September 1, 2025, and is expected to succeed Mr. Curtis as Chief Financial Officer upon Mr. Curtis’s retirement from such position.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.